Diabetes Care, Vol 23, Issue 12 1725-1730, Copyright © 2000 by American Diabetes Association

ARTICLES

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy

L Tarnow, P Rossing, C Jensen, BV Hansen and HH Parving
Steno Diabetes Center, Gentofte, Denmark. lise.tarnow@dadlnet.dk

OBJECTIVE: To compare the long-term effect on kidney function of a long-acting calcium antagonist (nisoldipine) versus a long-acting ACE inhibitor (lisinopril) in hypertensive type 1 diabetic patients with diabetic nephropathy. RESEARCH DESIGN AND METHODS: We performed a 4-year prospective, randomized, double-dummy controlled study comparing nisoldipine (20-40 mg once a day) with lisinopril (10-20 mg once a day). The study was double-blinded for the first year and single-blinded thereafter. The study included 51 hypertensive type 1 diabetic patients with diabetic nephropathy. Three patients dropped out during the first month; results for the remaining 48 patients are presented. RESULTS: At baseline, the two groups were comparable: glomerular filtration rate (GFR) was 85 +/- 5 and 85 +/- 6 ml x min(-1) x [1.73 m](-2); mean 24-h ambulatory blood pressure was 108 +/- 3 and 105 +/- 2 mmHg, and albuminuria was 1,554 mg/24 h (95% CI 980-2,465) and 1,033 mg/24 h (760-1,406) in the lisinopril and nisoldipine groups, respectively. Mean 24-h arterial blood pressure during the study did not differ between the lisinopril and nisoldipine groups (100 +/- 2 and 103 +/- 1 mmHg, respectively). The time-course of albuminuria differed between groups (P < 0.001). Whereas initiation of treatment with lisinopril resulted in a reduction from baseline albuminuria by 52% (95% CI 14-73), albuminuria in the nisoldipine group did not change throughout the study GFR declined in a biphasic manner with an initial (0-6 months) reduction of 1.3 +/- 0.3 ml x min(-1) x month(-1) in the lisinopril group compared with 0.2 +/- 0.4 ml x min(-1) x month(-1) in the nisoldipine group (P < 0.01). The subsequent sustained decline (6 to 48 months or the end of treatment) was identical in the two groups: 0.5 +/- 0.1 ml min(-1) x month(-1) (NS). Two patients in the lisinopril group and three patients in the nisoldipine group entered therapy for end-stage renal failure. CONCLUSIONS: Long-term treatment with lisinopril or nisoldipine has similar beneficial effects on progression of diabetic nephropathy in hypertensive type 1 diabetic patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Yasuda, D. Ando, N. Hirawa, S. Umemura, and O. Tochikubo Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy Diabetes Care, August 1, 2005; 28(8): 1862 - 1868. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Diabetic Nephropathy Diabetes Care, March 1, 2005; 28(3): 745 - 751. [Full Text] [PDF]

				M. J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S42 - S47. [Abstract] [Full Text] [PDF]

				G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11. [Abstract] [Full Text]

				G. Deferrari, M. Ravera, L. Deferrari, S. Vettoretti, E. Ratto, and D. Parodi Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S224 - 229. [Abstract] [Full Text]

				P. Swales and B. Williams Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 79 - 89. [Abstract] [PDF]

				H. Herlitz, K. Harris, T. Risler, G. Boner, J. Bernheim, J. Chanard, and M. Aurell The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2158 - 2165. [Abstract] [Full Text] [PDF]